Montanide ISA-51 was also used as adjunctive immunotherapy in an early-phase trial (NOA16; n = 32; NCT02454634) assessing the safety of an IDH1(R132H)-specific peptide vaccine in patients with another primary central nervous system tumor (IDH1 mutant glioma). Here, IDH1 is linked to central nervous system cancer.